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Abstract
Background: While hypertension is a common and treatable health problem, adherence to antihypertensive medication
remains a challenge. This study examines the hypothesis that workplace social capital may influence adherence to
antihypertensive medication among hypertensive employees.
Methodology/Principal Findings: We linked survey responses to nationwide pharmacy records for a cohort of 3515
hypertensive employees (mean age 53.9 years, 76% women) who required continuous antihypertensive drug therapy (the
Finnish Public Sector study). A standard scale was used to measure workplace social capital from co-workers’ assessments
and self-reports in 2000–2004. Non-adherence to antihypertensive medication was determined based on the number of
days-not-treated at the year following the survey using comprehensive prescription records. Negative binomial regression
models were conducted adjusting for socio-demographic characteristics, duration of hypertension, behaviour-related risk
factors, and co-morbid conditions. The overall rate of days-not-treated was 20.7 per person-year (78% had no days-not-
treated). Higher age, obesity, and presence of somatic co-morbidities were all associated with better adherence, but this
was not the case for co-worker-assessed or self-reported workplace social capital. The rate of days-not-treated was 19.7 per
person-year in the bottom fourth of co-worker-assessed workplace social capital, compared to 20.4 in the top fourth. The
corresponding rate ratio from the fully-adjusted model was 0.95 (95% confidence interval (CI) 0.58–1.56). In a subgroup of
907 new users of antihypertensive medication this rate ratio was 0.98 (95% CI 0.42–2.29).
Conclusions/Significance: We found no consistent evidence to support the hypothesized effect of workplace social capital
on adherence to drug therapy among employees with chronic hypertension.
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Introduction
Hypertension is an increasingly common health problem
affecting currently one billion people worldwide [1]. Although
effective medicines are available to control high blood pressure,
adherence to treatment remains a major problem [2]. The extent
of hypertensive patients who adhere to treatment (i.e. take
medications as prescribed) [2,3] is estimated to be 50% to 90%
[4–9]. Lack of treatment adherence results in suboptimal blood
pressure control, adverse cardiovascular outcomes, and health care
costs that could have been avoided [2,4,10,11]. Researchers have
identified several correlates of adherence, including patient
characteristics, the quality of the patient-clinician relationship,
severity of disease, access to health care, and treatment regimen
[2–4,12]. Recent studies also suggest that social support may
facilitate treatment adherence [2,5,13].
An important extension of the evidence linking social relation-
ships to health outcomes is the growing literature on social capital
and health. Social capital is defined as the features of social
structures which act as resources for individuals, including
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16]. Both low social capital and uncontrolled blood pressure have
been linked to cardiovascular disease morbidity and mortali-
ty[11,17,18]. However it is unclear whether poor adherence to
antihypertensive medication therapy could be one of the potential
mechanisms linking low social capital to adverse cardiovascular
outcomes.
In theory, social capital may influence medication adherence
through: (a) the provision of effective social support networks for
the exchange of health promoting information and access to
resources outside the individual’s own network [19–21]; (b) social
engagement in a meaningful social context that promotes positive
psychological states to enhance motivation for self-care and
appropriate health service utilization [22,23]; and (c) shared
norms and values around health-related behaviours [24,25]. To
date, at least two studies have examined the relationship between
social capital and the use of antihypertensive medication [26,27].
However, both of these studies used self-reports to assess exposure
and outcome and were thus subject to common method bias.
Furthermore, the studies assessed social capital via social
participation in the community among working and retired
people. It can be argued that for working populations spending
an increasing amount of their time at work, workplace may also
represent a meaningful source of social capital [28,29]. However,
we are not aware of any previous studies examining the hypothesis
that social capital in work context may promote adherence to
antihypertensive drug therapy.
The aim of the present study was to examine the hypothesis that
workplace social capital may influence adherence to antihyper-
tensive medication in a prospective cohort study of 3515
hypertensive men and women who responded to a survey of
workplace social capital. We linked their responses to nationwide
pharmacy records of filled prescriptions for antihypertensive
medication and followed up participants for one year to examine
the rates of days-not-treated as an objective indicator of non-
adherence to treatment.
Methods
Ethics statement
The Ethics Committee of the Finnish Institute of Occupational
Health approved the study.
Study design
We used data from the Finnish Public Sector study, which
includes the entire personnel in the municipal services of 10 towns
and within 6 hospital districts in Finland [30]. For this study, we
included 66,418 employees who responded to a survey of
workplace social capital in 2000–2002 and/or 2004 (a total of
79% of the eligible employees responded at least once). In case of
repeat responses, the more recent one was used in the analysis.
Personal identification numbers were used to link all study
participants to national prescription and health registers from
1994 through 2005.
Of the respondents, we identified those who had physician-
verified hypertension during the survey year, and who were alive at
least one year after the survey year (total n=4538). We excluded all
896 employees of one town for whom prescription data were not
available because their medication costs were covered by the
employer, 120 participants due to missing data on workplace social
capital, and 7 participants who had died before the beginning of the
1-year follow-up which ran from January 1 following the survey
year. Thus, the final analytic sample comprised 3515 hypertensive
employees (76% women, mean age 53.9 years, range 22–66).
Case ascertainment for hypertension
Hypertension and its duration were defined based on entitle-
ment to special reimbursement. In Finland, the National Health
Insurance administered by the Social Insurance Institution (SII)
covers all permanent residents regardless of age, wealth, or
employment status. Residents with chronic and severe hyperten-
sion are eligible for lower copayments for antihypertensive drugs.
Currently, 72% of the costs of medicines are reimbursed after a
fixed deductible by purchase with annual maximum copayments
of around 600 Euros, provided the person is listed in the Drug
Reimbursement Register maintained by the SII. In order to
receive special reimbursement, the patient must submit a doctor’s
certificate to SII stating the illness, and the medication needed to
treat it. For hypertension, the current criteria are stricter than the
guidelines for treatment of hypertension [11], and include
documentation of repeated blood pressure measurements of
$105 mmHg diastolic, or $95 mmHg diastolic with signs of
complications or other cardiovascular risk factors, or
$200 mmHg systolic. Special reimbursement can be granted
only after 6 months of surveillance with lifestyle counselling
followed by 6 months of drug therapy.
Workplace social capital
Workplace social capital was assessed with an 8-item self-
assessment scale designed to measure social capital in the workplace
[31]. Using a 5-point Likert-scale, the participants assessed
workplace social capital, defined as the shared values, attitudes,
and norms of trust and reciprocity as well as practices of collective
action in their work unit [31]. As previously [32,33], we assessed
social capital in two alternative ways: (a) using each individual’s own
assessment, and to minimise subjectivity bias, (b) summing up the
assessment of co-workers, but excluding the individual’s own
assessment. We calculated the mean of the individual items to
construct a scale ranging from 1 to 5 with higher score indicating
high social capital. Prior psychometric evaluation in the Finnish
Public Sector Study has demonstrated the scale to have high
internal consistency (Cronbach’s alpha 0.88) and rwg index (0.88)
indicating significant within-unit agreement [31].
Assessment of adherence to antihypertensive medication
Adherence to antihypertensive medication was assessed from
filled prescriptions for antihypertensive drugs recorded in the Drug
Prescription Register. The automated pharmacy dispensing data
are operated under a single system and cover virtually all filled out-
patient prescriptions from pharmacies in Finland. Pharmacy refill
data of antihypertensive drugs were extracted for the year
following the survey year, and included a listing of all
antihypertensive prescriptions filled, the dispensing date, the
quantity dispensed in Defined Daily Dosages (DDDs), and the
drug class according to the WHO Anatomical Therapeutic
Chemical (ATC) classification for codes C02 (antihypertensives),
C03 (diuretics), C07 (beta blockers), C08 (calcium channel
blockers), and C09 (ACE inhibitors). DDD is a globally unified
measurement unit, defined as the assumed average maintenance
dose per day for a drug used for its main indication in adults [34].
We used a refill-sequence model of adherence to quantify the
duration of treatment [35]. Thus, we measured the total duration
of consecutive refills, using 100 DDDs as a maximum for a refill
(up to 3 months supply of medications can be reimbursed during a
single transaction in the Finnish reimbursement legislation) and
added 50 days to all refills to prospectively fill the gaps between
subsequent purchases [35,36]. This grace period for the gap in
medication implies that the patients treated with half of the
defined daily dose are correctly assigned as having 100 days of
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gaps, i.e. days-not-treated, between subsequent prescriptions in the
sequence of all refill dates, assuming that an individual has not
discontinued drug therapy at a given point in time if his/her
dispensed supply from the last redemption has not elapsed or if it
elapsed within the last 50 days. We excluded periods of inpatient
hospital admissions during which the medication is provided by
the hospital. The outcome, days-not-treated, indicated non-
adherence to drug therapy and was treated as a continuous
variable in the analyses [37,38].
Covariates
Participants’ age, sex, socioeconomic status (SES), type of job
contract (permanent vs. temporary), type of employer (municipal-
ity vs. hospital), and geographic area (Southern, Middle or
Northern Finland, based on the location of the workplace) were
derived from employers’ registers. SES was divided into three
categories according to the occupational classification of Statistics
Finland, i.e. upper grade non-manual workers (e.g. head nurses,
teachers), lower grade non-manual workers (e.g. practical nurses,
technicians), and manual workers (e.g. cleaners, maintenance
workers). Marital status (married or cohabiting vs. other) was
derived from survey responses. Standard questionnaires were used
to assess behaviour-related risk factors: obesity (body mass
index$30, calculated as weight in kilograms divided by height
in meters squared), smoking (current vs. ex- or never), excess
alcohol use (.210g/wk) [39], and physical inactivity (,2 MET-
hours/wk, MET=metabolic equivalent tasks) [40].
The presence of co-morbid physical illnesses was based on
documentation of the condition in the SII, the National Hospital
Discharge Register, or the Finnish Centre for Pension for
entitlement to special reimbursement for the costs of medication,
sickness absence or disability pension or the main diagnoses of
hospital discharge. These conditions included diabetes mellitus,
heart failure, coronary heart disease, cardiac arrhythmia, and
cerebrovascular diseases. Notifications of diagnosed cancer were
obtained from the Finnish Cancer Registry which compiles all
cancer notifications in Finland. Co-morbid conditions were
encoded as ‘yes’ if any data on pre-existing disease was found
during four years preceding the follow-up. Co-morbid depression
was identified based on documentation of any of the following: 1)
long term (.90 days) work disability (sickness absence or disability
pension), 2) hospital admission due to depression, 3) pharmacy
records of filled prescriptions of at least 30 defined daily dosages of
antidepressants (ATC code N06) during any of the four years
preceding the follow-up, or 4) if the participant responded as being
diagnosed with depression in the survey.
Statistical analysis
As of April 2003, pharmacy personnel have been allowed to
switch to generic drug formulations to lower total prescription
drug costs in Finland, additionally leading to smaller copayments
to individuals, factor suggested to influence adherence [7]. We
took this into account in the analyses by adjusting the models for
the survey year. We examined the age- and survey-year-adjusted
differences in rates of days-not-treated as a function of the cohort
characteristics using analysis of variance. We calculated rate ratios
(RR) and their 95% confidence intervals (CI) for the days-not-
treated using negative binomial regression models to take into
account the skewness of the outcome [41], allowing for over-
dispersion. We conducted the analyses separately for self-reported
and co-worker-assessed social capital, adjusting for age, survey
year, sex, socioeconomic position, marital status, type of job
contract, type of employer, area of residence, duration of
hypertension, behaviour-related risk factors, and co-morbid
physical illness and depression at baseline. We tested whether
sex or SES modified the association by adding the interaction
terms sex*workplace social capital and SES*workplace social
capital in the model of main effects, but we did not find any
evidence of an effect modification (all p-values .0.05). Potential
predictors of non-adherence were considered statistically signifi-
cant at 95% confidence interval level (two-sided p,0.05).
Sensitivity analyses
We conducted three sets of sensitivity analyses. First, as 80% of
days treated is commonly used as a cut-point in adherence studies
[3,7], we tested the robustness of the findings by dichotomizing the
outcome as less than 80% of days treated versus other. Using this
binary outcome, we then conducted logistic regression models to
calculate odds ratios (OR) for the risk of non-adherence associated
with self-assessed and co-workers’ assessment of workplace social
capital. Second, because the effects of workplace social capital on
health may vary by dimension [42], we examined the vertical (i.e.
employees’ relations with their employers and supervisors) and
horizontal (i.e. social contacts, cooperation and trust in relation to
co-workers) components of workplace social capital separately. We
determined the vertical or horizontal component of workplace
social capital as in our previous study [43], divided the co-worker
assessed and self-reported ratings into quartiles, and examined
whether they were associated with non-adherence with negative
binomial regression models. Third, we restricted the sample to 907
(77% women) new users of antihypertensive medication because
long-term users may differ from new users in terms of baseline risk;
there is also evidence to suggest that adherence reduces over time
[4,6]. We traced those who were newly granted special
reimbursement for hypertension after responding to a survey in
2000–02 or 2004, followed their adherence to antihypertensive
medication during the first year of treatment starting from the date
of granting special reimbursement, and repeated the main analysis
using negative binomial regression models adjusting for age and
year of treatment, and then for all covariates.
All statistical analyses were conducted with SAS 9.13 statistical
software (SAS Institute, Inc., Cary, NC, USA).
Results
The baseline characteristics of the 828 hypertensive men and
2687 women are shown in Table 1. Of them, 14% were smokers
and 30% obese, 14% had been diagnosed with physical illnesses,
and 20% with depression before the adherence follow-up begun.
Participants had been treated for hypertension for a mean of 9.0
years (range 1–33) as defined from the duration of entitlement to
special reimbursement. The means of self-assessed and co-workers’
assessed workplace social capital were 3.56 (standard deviation
(SD) 0.78, range 1–5) and 3.57 (SD 0.39, range 1.38–5),
respectively.
The overall rate of days-not-treated was 20.7 per person-year
(range 0–365 days). A total of 78% of the participants had no days-
not-treated according to the Drug Prescription Register.
We did not find statistically significant differences in the rate of
days-not-treated between men and women, by marital status, type
of job contract or employer, residential area, or between
socioeconomic groups (Table 1). Smoking, physical inactivity
and heavy alcohol use were not associated with adherence either.
In contrast, each 5-year increase in age reduced the rate of days-
not-treated by 14% (RR 0.86, 95% CI 0.77–0.96). Obesity and the
presence of somatic co-morbidity were also associated with an
improved adherence: adjusted for age and survey year, rate ratios
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and 0.59 (95% CI 0.37–0.94) for the participants with somatic co-
morbidities compared to employees without these conditions.
Table 2 shows that neither co-worker assessed nor self-reported
workplace social capital was associated with adherence to
antihypertensive medication at 95% confidence level. The rate
Table 1. Baseline characteristics and their association with non-adherence to antihypertensive medication in 3515 hypertensive
employees, the Finnish Public Sector Study, 2000–2005.
Days-not-treated
Characteristic N (%) Rate per 1 person-year* RR (95% CI)*
Sex
Women 2687 (76) 20.4 1.00
Men 828 (24) 21.7 1.06 (0.73–1.55)
Socioeconomic status
Higher non-manual 799 (23) 20.0 1.00
Lower non-manual 1843 (52) 22.0 1.15 (0.77–1.72)
Manual workers 871 (25) 18.6 0.92 (0.58–1.46)
Marital status
Married 2638 (76) 20.7 1.00
Not married 822 (24) 21.8 1.07 (0.73–1.56)
Type of job contract
Permanent 3190 (93) 20.2 1.00
Temporary 246 (7) 25.2 1.23 (0.65–2.33)
Type of employer
Municipality 2238 (64) 19.7 1.00
Hospital 1277 (36) 22.4 1.13 (0.80–1.59)
Geographical area
Southern Finland 1919 (55) 20.7 1.00
Middle Finland 869 (25) 16.2 0.74 (0.50–1.10)
Northern Finland 727 (21) 26.0 1.20 (0.79–1.83)
Smoking
No 2919 (86) 21.0 1.00
Yes 481 (14) 21.2 1.00 (0.63–1.60)
BMI $30
No 2367 (70) 24.2 1.00
Yes 1034 (30) 12.4 0.51 (0.36–0.72)
Heavy alcohol use
No 3097 (89) 21.4 1.00
Yes 398 (11) 15.1 0.68 (0.41–1.13)
Physical inactivity
No 2251 (65) 22.7 1.00
Yes 1228 (35) 17.4 0.75 (0.53–1.04)
Co-morbid physical illness{
No 3029 (86) 21.9 1.00
Yes 486 (14) 13.3 0.59 (0.37–0.94)
Co-morbid depression
No 2804 (80) 19.8 1.00
Yes 711 (20) 24.3 1.24 (0.84–1.85)
Age (years, mean, SD) 53.9 (6.6) 0.86 (0.77–0.96)**
Duration of hypertension (years, mean, SD) 9.0 (6.3) 1.07 (0.94–1.22)**
RR; rate ratio, CI; confidence interval, SD; standard deviation.
*Adjusted for age and survey year.
**per 5-year increase.
{Diabetes mellitus, coronary insufficiency, coronary heart disease, cardiac arrhythmias, cerebrovascular disease.
doi:10.1371/journal.pone.0024732.t001
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of co-worker-assessed workplace social capital, compared to 20.4
in the top fourth. The corresponding rate ratio, adjusted for socio-
demographic characteristics, duration of hypertension, behaviour-
related risk factors, and co-morbid conditions was 0.95 (95% CI
0.58–1.56). For self-reported workplace social capital, the rate of
days-not-treated was 23.2 among employees in the lowest quartile,
whereas it was 21.7 for those reporting the highest levels. The
corresponding rate ratio from the fully-adjusted model was 1.17
(95% CI 0.72–1.92).
The results from the sensitivity analysis were consistent with the
main findings. Modelling the risk of less than 80% of days-treated
as the outcome and adjusting for all the covariates showed that
employees in the lowest quartile of co-worker assessed workplace
had no excess risk of non-adherence (OR 1.06, 95% CI 0.66–1.38)
compared to those in the highest quartile. For the lowest levels of
self-reported workplace social capital, the odds ratio from the fully-
adjusted model was 1.16 (95% CI 0.81–1.66). Similarly, neither
co-worker assessed nor self-reported vertical or horizontal
component of workplace social capital were associated with
adherence; the rate ratios varied between 1.00 and 1.12, and all
95% confidence intervals included unity.
In the subcohort of 907 new users of antihypertensive
medication, the overall rate of days-not-treated was 18.7 per
person-year during the first year of treatment when entitled to
special reimbursement for the costs of medication. Table 3 shows
that among these new users of antihypertensive medication there
was no excess risk of non-adherence associated with co-worker
assessed or self-reported workplace social capital. The rate ratio of
days-not-treated was 0.98 (95% CI 0.42–2.29) for low vs. high co-
worker assessed workplace social capital and 1.43 (95% CI 0.60–
3.40) for low vs. high self-reported social capital.
Discussion
In this cohort of 3500 hypertensive employees, we found no
consistent evidence to support the hypothesis that workplace social
capital would be associated with adherence to antihypertensive
medication. This was true for all and new users of antihypertensive
medication, for self-assessed and co-workers’ assessment of
workplace social capital, and for its vertical and horizontal
components.
Our results are in line with Johnell et al. who found no robust
association between social participation in the community and
adherence to antihypertensive medication among the elderly [26].
Similarly, Merlo et al. found no neighbourhood effect of social
participation on self-reported antihypertensive medication use
among women [27]. In our study, low self-reported social capital
was non-significantly associated with non-adherence, whereas the
association of co-worker-assessed social capital and adherence was
practically null. Given that we had sufficient power to detect a
meaningful association between social capital and adherence,
these null results suggest that workplace social capital does not
explain non-adherence to pharmacotherapy in hypertensive
working populations.
It is important to consider alternative explanations for our
results. The American Society of Hypertension and empirical
studies have highlighted that factors related to the health care
system are undervalued as contributors to (in)sufficient adherence,
as access to health care services may vary among health care
systems leading to cost-related non-adherence [4,44]. In Finland,
all citizens have unrestricted access to health services, including
partial or complete reimbursement of purchased medicines. In
these circumstances it may be that social capital in the workplace
promotes regular check-ups and help seeking in the first place
rather than continued adherence to medication [22,43]. Once a
patient has commenced long-term therapy, it is possible that other
characteristics, such as age, overall life style and, psychological
traits, may affect treatment adherence, as demonstrated in a
previous study in this cohort [41].
Imprecise measurement of the exposure or the outcome may
contribute to null findings. It is unlikely that the social capital
measure is subject to appreciable measurement error because we
also assessed co-workers’ perceptions of workplace social capital in
the same work unit, thus reducing the possibility of common
Table 2. Association between workplace social capital and non-adherence to antihypertensive medication in 3515 hypertensive
employees, the Finnish Public Sector Study, 2000–2005.
Days-not-treated
Workplace social capital Rate per 1 person-year
Model 1
RR (95% CI)*
Model 2
RR (95% CI)*
Model 3
RR (95% CI)*
Self-assessed
1 (low) 23.2 1.03 (0.65–1.65) 1.13 (0.70–1.83) 1.17 (0.72–1.92)
2 19.2 0.82 (0.52–1.30) 0.91 (0.57–1.45) 0.85 (0.53–1.38)
3 18.9 0.87 (0.54–1.39) 0.94 (0.58–1.52) 1.04 (0.62–1.73)
4 (high) 21.7 1.00 1.00 1.00
Co-workers’ assessment
1 (low) 19.7 1.00 (0.63–1.57) 0.97 (0.60–1.57) 0.95 (0.58–1.56)
2 21.2 1.05 (0.66–1.66) 1.04 (0.64–1.67) 0.92 (0.56–1.52)
3 21.4 1.04 (0.66–1.65) 0.96 (0.60–1.55) 0.80 (0.48–1.32)
4 (high) 20.4 1.00 1.00 1.00
*RR; rate ratio, CI; confidence interval.
Model 1 adjusted for age and survey year.
Model 2, as Model 1, additionally adjusted for sex, socioeconomic and marital status, type of job contract, type of employer, geographical area, and the duration of
hypertension.
Model 3, as Model 2, additionally adjusted for smoking, excess alcohol use, obesity, physical inactivity, and co-morbid physical illness and depression.
doi:10.1371/journal.pone.0024732.t002
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the workplace social capital measure has successfully predicted
other health outcomes, such as depression, in this dataset [32,33].
By and large, the measurement of adherence in hypertension is
problematic because no direct measures, such as biological
markers measured from the blood, are available [3]. We did not
use self-reports of adherence which are subject to recall bias and
social desirability with the tendency to overestimate adherence
[6,45]. Comprehension of monitoring of adherence as in
randomised controlled trials may itself enhance adherence [9].
Measuring adherence objectively from pharmacy refill data are
considered highly accurate and more complete than medical
records and information elicited from questionnaires [46]. In our
study, the rates of adherence observed were in line with previous
studies from the UK [5], US [7,8], and Spain [9] reporting days
covered rather than using an arbitrary cut-point to determine
adherence. Furthermore, we found, in agreement with previous
studies, that older age, obesity, and co-occurrence of cardiovas-
cular co-morbidities were each associated with better adherence
[47,48]. Patients with multiple cardiovascular risk factors may be
more motivated to adhere with their therapy or have more severe
of hypertension [47,48].
Limited variation in the exposure may lead to an underestima-
tion of associations and potentially contribute to false null findings.
All employees in our study were working in the service of public
hospitals or municipalities. It is possible that the workplace culture
in these public sector workplaces is more similar than in other
types of workplace (for example in private for-profit companies),
resulting in reduced variation in workplace social capital.
However, the range and standard deviation of the social capital
measures suggest that limited variation may not be a major
problem in these data
Low statistical power can prevent detection of small effects. Our
study was based on a relatively large sample and the absolute
differences in non-adherence days between social capital groups
were all within 6 days per year. This suggests that there was no
clinically meaningful effect of workplace social capital on
adherence behaviour. Still, based on the results of this study, we
cannot refute the possibility that social capital in other contexts
might be associated with adherence to antihypertensive medica-
tion or treatment adherence in other diseases.
Strengths and limitations
We employed data from a large cohort of workers with
physician-verified hypertension and need for continuous antihy-
pertensive medication, successfully linked to a comprehensive
population level prescription register to enable a 12-month
prospective follow-up. All participants were covered by the
Finnish National Health Insurance, thus avoiding selection bias
due to insurance coverage or varying time of insurance coverage
which is possible in commercial health insurance plans. We
investigated both prevalent and new users because barriers to good
adherence may differ for newly-diagnosed patients versus those
with long-standing treatment for hypertension [6,7]. We used a
psychometrically validated multi-item measure to assess workplace
social capital. We measured medication adherence objectively
from pharmacy refill data. Rates of refilled prescriptions are
considered valid as measures of gaps in medication supply within a
closed pharmacy system provided that the refills are measured at
several points in time [3,49].
However, the results need to be interpreted in the light of
several limitations. First, pharmacy dispensing records provide an
indirect measure of adherence and we could not ascertain whether
the medication was actually taken. Second, the participants were
covered by the Finnish National Health Insurance which may
compromise generalisability of the findings to uninsured workers.
Third, qualifying for special reimbursement required blood
pressure levels of Stage II hypertension or Stage I with other
cardiovascular risk factors or co-morbidities [11]. Hence, we do
not know whether workplace social capital contributes to
adherence in milder cases of hypertension. Fourth, we assessed
workplace social capital at baseline only, and we did not assess
changes in social capital in relation to changes in adherence
behaviour. Fifth, when prescription registries are used to define
episodes of medication use, apparent gaps in treatment can occur.
By filling the gaps, we avoided bias from embedded gaps due to a
Table 3. Association between workplace social capital and non-adherence to antihypertensive medication in a subcohort of 907
employees with incident hypertension, the Finnish Public Sector Study, 2000–2005.
Days-not-treated
Workplace social capital Rate per 1 person-year
Model 1
RR (95% CI)*
Model 2
RR (95% CI)*
Self-assessed
1 (low) 24.5 1.56 (0.71–3.44) 1.43 (0.60–3.40)
2 20.7 1.38 (0.64–3.00) 1.27 (0.54–2.94)
3 13.4 0.80 (0.78–1.69) 0.92 (0.40–2.13)
4 (high) 18.1 1.00 1.00
Co-workers’ assessment
1 (low) 18.4 1.04 (0.48–2.24) 0.98 (0.42–2.29)
2 21.0 1.23 (0.57–2.64) 1.08 (0.47–2.47)
3 15.3 0.86 (0.40–1.85) 0.70 (0.31–1.60)
4 (high) 18.1 1.00 1.00
*RR; rate ratio, CI; confidence interval.
Model 1 adjusted for age and treatment year.
Model 2, as Model 1, additionally adjusted for sex, socioeconomic and marital status, type of job contract, type of employer, geographical area, duration of
hypertension, smoking, excess alcohol use, obesity, physical inactivity, and co-morbid physical illness and depression.
doi:10.1371/journal.pone.0024732.t003
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have misclassified participants with terminal gaps, i.e. discontinu-
ing the medication without finishing the supply [50]. If the 50 days
we used for filling the gaps is too long a period, we have counted
those non-adherent as adherent; conversely, if the period is too
short, we have missed individuals who continued taking the
medication, i.e. who were adherent. Non-differential misclassifi-
cation of the outcome, which can be assumed to be the case with
the Prescription Register, is likely to bias the measures of
associations towards the null. Finally, there may be a tendency
of those employees whose adherence is poor to develop
complications of high blood pressure and to leave employment
[10,50]. However, our follow-up covered both employed and
unemployed population, reducing the healthy worker effect related
to occupational cohorts [51].
Conclusions
In this paper, we report null results of the relationship between
workplace social capital and adherence to antihypertensive
medication. Reporting null results may provide balance for the
social capital research area not to produce publication bias and not
to show social capital in a too favourable light. We wish not to
guard research away from studying social capital in workplaces,
but instead, encourage comparative work. To our knowledge, this
is the first and only investigation on this topic in the work context
to date. As the meaning of workplace social capital may differ by
cultural background or branch of industries, further studies in
other cohorts and contexts are needed to refute the overall
hypothesis that social capital is associated with adherence to
antihypertensive medication.
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